ArticleTherapeutic advances in gastroenterology2026

Efficacy and safety of risankizumab in moderate-to-severe Crohn's disease: a systematic review and meta-analysis.

Hafsa Nasim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.